4.51

0.22% -0.03

Seres Therapeutics Inc (MCRB)

Overview News Price History Option Chain Financials Discussions Forecast

Seres Therapeutics Inc stock is traded at $4.51, with a volume of 34,092. It is down -0.22% in the last 24 hours and down -15.01% over the past month. Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.

Previous Close:

$4.54

Open:

$4.55

24h Volume:

34,092

Relative Volume:

0.40

Market Cap:

$45.20M

Revenue:

$1.15M

Net Income/Loss:

$-46.90M

P/E Ratio:

-0.8987

EPS:

-5.0182

Net Cash Flow:

$-42.37M

1W Performance:

-9.40%

1M Performance:

-15.01%

6M Performance:

-45.29%

1Y Performance:

-72.86%

1-Day Range:

$4.43

$4.62

1-Week Range:

$4.43

$4.94

52-Week Range:

$4.43

$29.98

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name

Seres Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

617 945 9626

Address

200 SIDNEY STREET, CAMBRIDGE, MA

Employee

Twitter

@SeresTX

Next Earnings Date

2026-08-05

Latest SEC Filings

MCRB's Discussions on Twitter

Compare MCRB vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MCRB Seres Therapeutics Inc	4.50	45.60M	1.15M	-46.90M	-42.37M	-5.0182
VRTX Vertex Pharmaceuticals Inc	515.31	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.34	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.59	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.54	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.30	39.31B	5.76B	514.49M	1.10B	4.4813

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-08-25	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-24-24	Downgrade	JP Morgan	Neutral → Underweight
Jun-26-23	Resumed	Oppenheimer	Outperform
Apr-21-23	Initiated	JP Morgan	Neutral
Jul-23-21	Downgrade	Goldman	Neutral → Sell
May-18-21	Resumed	Goldman	Neutral
Mar-05-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Sep-18-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Aug-11-20	Upgrade	Jefferies	Hold → Buy
Apr-30-19	Initiated	Jefferies	Hold
Oct-22-18	Initiated	Chardan Capital Markets	Buy
Oct-13-17	Initiated	Oppenheimer	Outperform
Aug-04-17	Reiterated	H.C. Wainwright	Buy
Feb-01-17	Reiterated	FBR & Co.	Outperform
Aug-12-16	Reiterated	FBR Capital	Outperform
Aug-01-16	Downgrade	BofA/Merrill	Buy → Neutral
Aug-01-16	Reiterated	H.C. Wainwright	Buy
Jul-29-16	Resumed	H.C. Wainwright	Buy
Mar-30-16	Initiated	FBR Capital	Outperform
Mar-03-16	Initiated	Guggenheim	Buy
Jan-25-16	Initiated	H.C. Wainwright	Buy
Oct-22-15	Upgrade	BofA/Merrill	Neutral → Buy
Jul-22-15	Initiated	Canaccord Genuity	Buy
Jul-21-15	Initiated	Goldman	Neutral
Jul-21-15	Initiated	Leerink Partners	Outperform

View All

Seres Therapeutics Inc Stock (MCRB) Latest News

Aug 16, 2026

Seres Therapeutics, Inc. Revenue Breakdown – NASDAQ:MCRB - TradingView

Aug 16, 2026

Aug 13, 2026

Seres TherapeuticsMay Offer Up To $300 Million Of Securities - TradingView

Aug 13, 2026

Aug 08, 2026

MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits

Aug 08, 2026

Aug 07, 2026